Quick Answer
4D Molecular Therapeutics, Inc. reported Stockholders Equity of $505.66 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $505.66M | -1.0% |
| 2024 | $510.61M | +65.9% |
| 2023 | $307.83M | +33.1% |
| 2022 | $231.34M | -27.5% |
| 2021 | $319.11M | +24.5% |
| 2020 | $256.39M | +451.4% |
| 2019 | -$72.97M | -164.5% |
| 2018 | -$27.59M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $368.98M | -33.3% | -12.3% |
| June 30, 2025 | $420.89M | -28.5% | -10.4% |
| March 31, 2025 | $469.72M | -21.8% | -8.0% |
| December 31, 2024 | $510.61M | +65.9% | -7.7% |
| September 30, 2024 | $552.95M | +67.6% | -6.0% |
| June 30, 2024 | $588.34M | +80.9% | -2.0% |
| March 31, 2024 | $600.56M | +174.7% | +95.1% |
| December 31, 2023 | $307.83M | +33.1% | -6.7% |
- 4D Molecular Therapeutics, Inc. showed a decrease of -1.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, 4D Molecular Therapeutics, Inc.’s stockholders equity has grown by 1933.0% (from -$27.59 million to $505.66 million).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: